Sinusitis Treatment Market Report Scope & Overview:

The Sinusitis Treatment Market was valued at USD 3.02 Billion in 2025 and is expected to reach USD 5.15 Billion by 2035, growing at a CAGR of 5.48% from 2026-2035.

The Sinusitis Treatment Market is poised for success owing to the increase in chronic rhinosinusitis patients, rapid adoption of biological agents for nasal polyps, and the rising use of minimally invasive procedures such as balloon sinuplasty. There is a paradigm shift from the use of cycle after cycle of antibiotics and steroids to the adoption of specific drugs for the treatment of underlying type 2 inflammation. Delivery systems via exhalation and steroid-eluting implants have helped in improving the drug delivery to the inaccessible sinus cavities. The role of AI in guiding surgery and stewardship of antibiotics has changed the approach of antibiotics for acute sinusitis.

In February 2026, Sanofi and Regeneron received FDA approval for Dupixent as the first and only medicine for allergic fungal rhinosinusitis in adults and children aged six years and older with prior sinonasal surgery. The approval extends biologic treatment to a new sinusitis subtype and widens the addressable patient pool.

Sinusitis Treatment Market Trends

• Rising adoption of biologics such as dupilumab and tezepelumab for nasal polyps.

• Growing shift toward office-based balloon sinuplasty over traditional sinus surgery.

• Increasing use of exhalation delivery systems for deeper intranasal steroid deposition.

• Expanding AI-guided navigation and visualization platforms for endoscopic sinus surgery.

• Growing antibiotic stewardship programs limiting empirical prescribing for acute sinusitis.

• Rising approvals of domestically developed biologics in China and other Asian markets.

U.S. Sinusitis Treatment Market Outlook:

The U.S. Sinusitis Treatment Market was valued at USD 1.05 Billion in 2025 and is expected to reach USD 1.73 Billion by 2035, growing at a CAGR of 5.12% from 2026-2035.

The U.S. sinusitis treatment market is growing owing to the high prevalence of sinusitis that affects about 12% of adults in America and the increasing adoption of innovative treatments. Chronic rhinosinusitis results in significant loss of productivity and increased medical costs, which, in turn, calls for the earlier adoption of biologics and minimally-invasive surgeries. Several biologics have been approved by the FDA for nasal polyps, such as Dupixent, Nucala, Xolair, and Tezspire, offering clinicians a variety of treatment options. The use of balloon sinuplasty in an office setting reduces costs relative to traditional surgery and attracts payers’ support. Medtronic, Stryker, and Olympus are some of the major players having extensive portfolios in U.S. ENT devices.

In October 2025, Amgen and AstraZeneca received FDA approval for Tezspire as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps in patients aged 12 years and older. Tezspire became the first biologic targeting thymic stromal lymphopoietin approved for this indication, supported by positive Phase 3 WAYPOINT trial results.

Sinusitis Treatment Market Segment Analysis:

• By Disease Type, the Chronic Sinusitis segment dominated the Sinusitis Treatment Market with approximately 56.84% share in 2025, while the Acute Sinusitis segment is the fastest growing with a CAGR of approximately 6.72%.

• By Treatment Type, the Antibiotics segment dominated the Sinusitis Treatment Market with approximately 38.47% share in 2025, while the Biologics segment is the fastest growing with a CAGR of approximately 11.36%.

• By Route of Administration, the Nasal segment dominated the Sinusitis Treatment Market with approximately 46.18% share in 2025, while the Injectable segment is the fastest growing with a CAGR of approximately 9.84%.

• By Distribution Channel, the Retail Pharmacies segment dominated the Sinusitis Treatment Market with approximately 44.27% share in 2025, while the Online Pharmacies segment is the fastest growing with a CAGR of approximately 7.62%.

By Disease Type, Chronic Sinusitis Leads, While Acute Sinusitis Grows Fastest

The chronic sinusitis segment dominated the Sinusitis Treatment Market in 2025, as chronic rhinosinusitis affects up to 12% of the global population and requires long-term, recurring treatment. Patients often need repeated courses of intranasal corticosteroids, saline irrigation, and antibiotics, along with surgery for severe cases. The subgroup with nasal polyps increasingly receives high-value biologics such as dupilumab, mepolizumab, omalizumab, and tezepelumab. Revision endoscopic sinus surgery and steroid-eluting implants add further value. These factors generate higher spending per patient than acute cases, supporting the segment’s leading share throughout the forecast period. Growing biomarker use also supports more personalized and effective treatment decisions.

The acute sinusitis segment is the fastest-growing disease type, supported by the very large number of acute episodes linked to colds, allergies, and seasonal respiratory infections each year. Improved diagnosis in primary care and urgent care centers is helping clinicians separate bacterial from viral cases, leading to more targeted use of antibiotics. Growing use of combination regimens that pair antibiotics with intranasal corticosteroids is improving symptom relief. Over-the-counter decongestants, analgesics, and nasal sprays are also widely used. Rising awareness, telemedicine access, and expanding healthcare coverage in emerging markets are expected to support strong growth in this segment. Pharmacists also guide self-care.

By Treatment Type, Antibiotics Lead, While Biologics Grow Fastest

The antibiotics segment dominated the Sinusitis Treatment Market in 2025 due to the continued use of antibiotics in the treatment of bacterial acute sinusitis and acute exacerbations of chronic disease. The first-line drugs include amoxicillin and amoxicillin-clavulanate, whereas doxycycline and others are used for patients who are allergic to penicillin. Prescriptions in primary care, urgent care, and ENT clinics ensure high revenues despite low generic prices. However, antibiotic stewardship initiatives and watchful waiting guidelines for uncomplicated cases reduce empirical prescribing, which will result in gradual decline in the segment's share in the forecast period. Rapid diagnostics will help improve prescribing practices.

Biologics is the fastest-growing treatment segment due to the availability of monoclonal antibodies as an effective therapy for patients with chronic rhinosinusitis with nasal polyps unresponsive to steroid and surgical treatments. Dupixent produced by Sanofi and Regeneron is the leading drug in the segment approved for adults, adolescents, and allergic fungal rhinosinusitis. Other available drugs include Nucala from GSK, Xolair from Novartis and Genentech, and Tezspire from Amgen and AstraZeneca. Stapokibart, a domestically produced biologic, has been approved in China to increase its availability in Asia. High prices, positive clinical results, and increasing indications will contribute to rapid growth in this segment.

By Route of Administration, Nasal Leads, While Injectable Grows Fastest

The nasal segment dominated the Sinusitis Treatment Market in 2025, comprising mainly of intranasal corticosteroid sprays, nasal saline irrigation, decongestant sprays, and antihistamine sprays, which form the base of sinusitis treatment. The administration of medicines to the site of inflammation helps provide quick symptom relief along with minimal side effects. Commonly used corticosteroids include fluticasone, mometasone, and budesonide sprays. XHANCE inhalation device from Optinose is available to deliver steroid sprays to sinuses and has been FDA-approved to treat chronic rhinosinusitis without nasal polyps. High availability and familiarity contribute to the sustained leadership of this segment. Generics further ensure affordability for most patients.

Injectables were the fastest-growing administration routes, driven by the quick adoption of subcutaneous biologics for chronic rhinosinusitis with nasal polyps. Some biologic medicines include Dupixent, Nucala, Xolair, and Tezspire and are available as injections which are given once every two or four weeks depending on the condition of the patient. Prefilled pens allow the injection to be self-administered by the patient in the comfort of their homes. They not only shrink the polyp but also help in improving nasal congestion and sense of smell while reducing the need for surgery and oral steroids. The latest approvals have increased the number of eligible populations, including adolescents and other sinusitis subtypes.

Regional Analysis:

North America Sinusitis Treatment Market Insights

North America accounted for approximately 39.84% of the Sinusitis Treatment Market in 2025, the largest share among all regions, supported by early adoption of biologics, strong payer coverage for minimally invasive surgery, and high sinusitis prevalence. The United States generates most regional revenue, with FDA approvals for several biologics for nasal polyps and allergic fungal rhinosinusitis. Office-based balloon sinuplasty delivers average savings of about USD 2,200 per case compared with traditional surgery, encouraging payer support. Leading pharmaceutical and device companies, including Sanofi, Regeneron, Amgen, Medtronic, and Stryker, maintain strong positions in the region. Strong specialist networks further support wider adoption.

Canada has remained consistent in its share due to its public healthcare system and pharmacoeconomics review, which guides the reimbursement of biologics where omalizumab is considered to be a cost-effective choice for appropriate patients. Mexico is a developing market because of its increasing middle-class population, access to healthcare through the private sector and an increase in medical tourism for ENT surgeries. Across the entire region, digital health solutions and telemedicine have increased the convenience of diagnosis and medication refills. The approvals of drug-free medical devices, such as SoundHealth's SONU band for children, continue to expand choices of treatment options. Nonetheless, antibiotic stewardship still restricts the number of prescriptions.

Europe Sinusitis Treatment Market Insights

Despite being the second-largest region after the US, Europe is still supported by countries like Germany, the UK, France, Italy, and Spain where universal healthcare systems provide access to sinuses treatments. The European Position Paper on Rhinosinusitis and Nasal Polyps provides harmonized diagnostic and treatment guidelines for the evidence-based application of corticosteroids, surgery, and biologics. This region has an advanced network of ENT specialists and equipped hospitals conducting endoscopic sinus surgery. Moreover, the European Medicines Agency has approved several biologics for nasal polyps and the health technology assessments affect reimbursement decisions and adoption rates in different countries of the region. Referral pathways among specialists improve the quality of care in patients.

Germany, the UK, and France are the leaders in adopting biologics because of their reimbursement pathways and wide specialist networks. Countries in Southern Europe such as Italy and Spain rapidly increase their adoption rate thanks to positive HTA. The CE mark for Medtronic’s Stealth AXiS surgical system in 2026 allowed extending ENT navigation in Europe and improving sinus surgery. Herbal remedies like Sinupret are often prescribed in Germany and other countries for acute sinusitis. However, the region still has to cope with restrictive cost-containment measures and increasing generics competition that affects the price of drugs. Biologics are the key growth drivers in Europe.

Asia-Pacific Sinusitis Treatment Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Sinusitis Treatment Market, anticipated to record a CAGR of around 7.36% during the forecast period from 2026 to 2035, due to rising air pollution, expanding healthcare infrastructure, and growing awareness of advanced therapies. China is the largest market in the region, supported by a large patient population, strong demand for image-guided endoscopic sinus surgery, and the December 2024 approval of stapokibart, the country’s first domestically developed biologic for nasal polyps. GSK’s approval of Nucala in China in 2025 further expanded biologic access in the region. Rising pollution levels also increase demand.

Japan appears to be an important market owing to its aging population, eosinophilic chronic rhinosinusitis, and extensive insurance coverage for biologics and surgical procedures. In India, there are promising signs of a growth driver owing to extreme pollution, a substantial number of patients, and domestic generic companies such as Cipla, Dr. Reddy’s, and Aurobindo. South Korea and Australia gain from their excellent ENT services along with quick uptake of treatments. Although a shortage of the workforce remains in certain areas, tele-mentoring and robotics have helped fill these gaps and are ensuring growth in the regional market throughout the forecast period.

MEA & Latin America Sinusitis Treatment Market Insights

The Middle East & Africa region represents a smaller but growing share of the Sinusitis Treatment Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, where dust storms, dry climates, and high allergy rates contribute to sinus disease. Government investments in specialty hospitals and expanding insurance coverage are improving access to advanced ENT procedures and biologics. Medical tourism in Dubai is also increasing demand for minimally invasive sinus surgery. South Africa anchors demand across the wider African continent, although limited ENT specialists and healthcare budgets restrict access to advanced treatments. Generic drugs remain dominant there.

Latin America is growing at a steady pace with Brazil being the frontrunner owing to its large population, extensive public health care system, and strong pharmaceutical industry. Argentina and Colombia are creating demands with their increasing private hospital infrastructure and increasing availability of ENT specialists. Mexico enjoys medical tourism and increasing availability of biologics in private healthcare. There is an increase in the number of sinusitis patients owing to the high prevalence of allergic rhinitis and urban pollution in the region. However, there are certain challenges in the adoption of premium treatment due to the high price of biologics, lack of reimbursement, and the wide use of generics and OTC drugs.

Market Dynamics:

Growth Drivers: Rising Disease Prevalence and Biologic Adoption

Market Growth in the Sinusitis Treatment is mainly fueled by the global increase in both acute and chronic rhinosinusitis. As much as 12% of the population in the world suffers from chronic rhinosinusitis. Moreover, in the US alone chronic rhinosinusitis causes about 20 missed working days annually. Increased incidence of sinus infections is caused by pollution in urban areas, allergies, and climate change. Aging populations are also increasing the number of patients with chronic conditions. Changes in sinonasal microbial flora due to COVID-19 are also causing persistent inflammatory symptoms among certain individuals. Therefore, they require more outpatient visits, surgical interventions, and prolonged medication treatment. Increased awareness helps to detect problems early.

Fast adoption of biologic therapies to treat chronic rhinosinusitis with nasal polyps is further contributing to the market growth. In SINUS-24 and SINUS-52 clinical trials, dupilumab demonstrated successful results, including alleviated symptoms and decreased surgical requirements. Recently approved treatments include Dupixent to be used in adolescents and allergic fungal rhinosinusitis, as well as Tezspire that can be used in case of nasal polyps. Minimally invasive treatments, such as balloon sinuplasty are highly effective and cost-efficient, since they cause less complications compared to conventional surgeries. Exhalation delivery systems and steroid-eluting implants are making it easier to treat patients that have no effect from conventional nasal sprays.

Restraints: Generic Competition and Antibiotic Stewardship

Increasing adoption of affordable generics and over-the-counter drugs continues to hinder market growth. Affordability of generics, such as azelastine-fluticasone, is leading to reduction of more than 45% in U.S. retail prices within a year following patent expiry. OTC nasal sprays and decongestants offer relief for symptoms of sinusitis comparable to several brands in terms of efficacy, leading to shift in spend to more affordable retail channels. Generics account for more than 70% prescriptions in developing economies, thereby impacting branded drug sales. Herbal treatment is helping certain patients avoid prescription drugs, further constraining the revenue growth. Pricing pressure is expected to remain high in all key markets.

Antibiotic resistance and antibiotic stewardship represent other constraints affecting the sinusitis market growth. Watchful waiting for uncomplicated acute sinusitis patients has become a part of guidelines recommended by clinicians in 2024. The CDC observes that in 2024, in 30% of cases with acute sinusitis, inappropriate antibiotics were prescribed. These instances will lead to stringent regulatory and payer actions to restrict misuse of antibiotics. High prices of biologics limit its adoption in several countries. Additionally, lack of otolaryngologist trained doctors restricts adoption of advanced procedures in emerging regions. Overall, the above factors will hamper the near-term growth in several emerging markets.

Opportunities: Expanding Biologic Indications and Integrated ENT Platforms

The growing number of biological indications offers tremendous potential for the market as it helps widen the addressable population by approval for adolescents, allergic fungal rhinosinusitis, as well as additional sinusesitis sub-types. Drugs like depemokimab, targeting the pathways of inflammation, may promise fewer doses. Biomarkers identifying the patients who are more prone to respond to some treatment help develop precision medicine and are more easily accepted by the payers. Domestically-made biologics in China and other markets in Asia will bring more opportunities in regard to cost-effectiveness. Companies with good scientific evidence supported by real-world research on the decreased amount of surgeries and steroids usage will be able to get better formulary statuses. Patient programs might help increase adherence rates.

On the other hand, the development of integrated platforms for ENT is a big opportunity for device companies. A bundle of AI-driven navigation, HD-visualization, sinus balloon dilation and disposable instruments is offered for the hospitals and ASCs. Alliances such as Medtronic and KARL STORZ alliance to combine visualization with AiBLE ENT platform are great examples of companies working to develop connected surgery workflow. Drug-free devices, including bioelectronic and neuromodulation devices can become alternatives in order to ease congestion. Growing investments of healthcare in the countries of Asia-Pacific and Middle East regions make the demand for new sinus solutions even higher.

Recent Developments:

• 2026, Medtronic received CE mark for its Stealth AXiS surgical system, expanding its connected ENT navigation platform for sinus surgery to European markets.

• 2025, GSK received approval from China’s National Medical Products Administration for Nucala (mepolizumab) to treat adults with chronic rhinosinusitis with nasal polyps.

• 2025, SoundHealth received FDA clearance for the SONU Band for pediatric use, offering a drug-free acoustic resonance option for nasal congestion relief.

• 2024, Keymed Biosciences received approval in China for stapokibart, the country’s first domestically developed biologic for chronic rhinosinusitis with nasal polyps.

• 2024, Optinose received FDA approval for XHANCE as the first prescription medication for chronic rhinosinusitis without nasal polyps in adults.

Sinusitis Treatment Market Key Players:

• Sanofi S.A.

• Regeneron Pharmaceuticals, Inc.

• AstraZeneca plc

• Amgen Inc.

• GSK plc

• Novartis AG

• Medtronic plc

• Stryker Corporation

• Olympus Corporation

• Integra LifeSciences Holdings Corporation

• Optinose (Paratek Pharmaceuticals)

• Cipla Limited

• Dr. Reddy’s Laboratories Ltd.

• Teva Pharmaceutical Industries Ltd.

• Bayer AG

• Aurobindo Pharma Limited

• NeilMed Pharmaceuticals, Inc.

• Keymed Biosciences Inc.

• Pfizer Inc.

• KARL STORZ SE & Co. KG

Sinusitis Treatment Market Report Scope: